Cite
HARVARD Citation
Stadler, W. et al. (2014). An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. 120 (7), pp. 976-982. [Online].